Actionable news
All posts from Actionable news
Actionable news in TROV: TrovaGene, Inc.,

Patient Case Report Demonstrating The Ability Of Trovagene'S Precision Cancer Monitoring Platform To Determine Early Drug Response Published In Cancer Discovery

The following excerpt is from the company's SEC filing.

Confirmation of BRAF V600E mutational status and quantitative monitoring of changes in urinary ctDNA used to assess response to novel combination drug therapy for colorectal neuroendocrine tumors

SAN DIEGO, April 15, 2016 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, announced today that a patient case report featuring use of the Company's Precision Cancer Monitoring® (PCM) technology was published in

Cancer Discovery

, a leading oncology journal. Dr. Samuel J. Klempner, Director of Precision Medicine at The Angeles Clinic and Research Insti tute in Los Angeles, authored the manuscript titled,

BRAF V600E Mutations in High Grade Colorectal Neuroendocrine Tumors May Predict Responsiveness to BRAF-MEK Combination Therapy

"This patient case supports using ctDNA from a urine sample to confirm the presence of the

mutation, and to regularly monitor changes in mutation frequency, especially in the first few weeks of a new drug regimen," stated Dr. Klempner. "Trovagene's liquid biopsy technology provided important evidence of early response to treatment with combination BRAF-MEK inhibitor therapy in

mutant high grade colorectal neuroendocrine tumors. This drug combination is undergoing clinical investigation across multiple tumor types and the information provided by non-invasive dynamic monitoring of ctDNA can be helpful in demonstrating that this novel treatment regimen is having its intended effect."

"We are very pleased with the

Cancer Discovery publication

, and the ability of our liquid biopsy technology to help physicians select the most appropriate therapy for their patients," stated Mark Erlander, Ph.D., chief scientific officer...